Markets News
Latest stock market news and real-time market analysis. Track S&P 500, Nasdaq, and Dow Jones movements, sector rotations, and breaking market events.
Moderna stock surges $3.3B after unveiling in vivo CAR-T for autoimmune disease
Moderna shares surged 13.9%, adding $3.3 billion in market value after the company unveiled an in vivo CAR-T candidate for autoimmune disease at its Science Day, though near-term sales remain absent.
Bloom Energy Plunges After Russell Index Switch
Bloom Energy shares fell 12.4% to $270.88 after exiting the Russell 2000 for the Russell Top 200, putting its high valuation under scrutiny amid heavy trading volume.
Ondas Shares Surge on Russell 3000 Entry and Resale Filing
Ondas shares jumped to $7.89 as the company joined the Russell 3000 index and filed to register 3.38 million acquisition-linked shares for resale, with daily volume caps.
Bradesco Shares Jump on 1.9% Payout, Loan Loss Concerns Linger
Bradesco shares surged 2.44% on heavy volume as a 1.9% interim dividend drew yield seekers, yet the stock remains 17% below its 52-week high amid rising loan-loss provisions.
Clearwater Analytics Delisted After $8.4B Take-Private, Options Settle for Cash
Clearwater Analytics' $8.4B take-private closed June 25 at $24.55/share, a 47% premium. CWAN delisted from NYSE; options settle for $2,455 cash per contract.
Sadot Group Shares Surge 75% on Massive Volume Amid Going Concern Doubts
Sadot Group (SDOT) soared 75% on volume 15x its share base, despite filings showing a tiny float, preferred stock, a large real estate option, zero Q1 commodity sales, and going concern doubts.
EchoStar's ECHO Debut Slumps on AT&T Cash Dependence, SpaceX Index Event
EchoStar's new ECHO ticker dropped 6.5% in its first two sessions, with the $20.25B AT&T cash representing 71% of equity. The stock rebounded 1.7% Friday as investors eye deal closing and SpaceX's Russell index addition.
SELLAS Life Sciences Soars on Heavy Short Interest Ahead of AML Trial Results
SELLAS Life Sciences (SLS) surged 6.3% to $11.19 as short interest climbed to 32.65% of float and trading volume doubled. The company amended executive severance terms and disclosed 78 of 80 events reached in its Phase 3 AML trial.
Centessa's Final Trade Puts Lilly CVR at 28% of Maximum Value
Centessa's final $40.50 trade implies a 28% value on its non-transferable CVR from the $38/share Lilly buyout, with only drug-approval payouts remaining.
Can-Fite BioPharma Surges on Japanese Patent Grant for Obesity Drug
Can-Fite BioPharma shares surged 17% premarket after Japan allowed a patent for Namodenoson in obesity, but the company's $6.61M market cap remains near the NYSE American delisting threshold.